Table II.
Univariate survival analysis of DSS in patients with endometrioid endometrial cancer (n=107).
| DSS | |||||||
|---|---|---|---|---|---|---|---|
| 95% CI | |||||||
| Variable | Patients, n | Estimate | Standard error | Lower bound | Upper bound | χ2 a | P-valuea |
| Age, years | 5.044 | 0.025 | |||||
| ≤60 | 61 | 65.241 | 1.178 | 62.932 | 67.550 | ||
| >60 | 46 | 63.722 | 1.118 | 61.532 | 65.913 | ||
| FIGO stage | 0.062 | 0.804 | |||||
| I/II | 77 | 65.108 | 0.899 | 63.347 | 66.869 | ||
| III/IV | 30 | 62.846 | 2.380 | 58.181 | 67.510 | ||
| Histological grade | 23.728 | <0.001 | |||||
| 1 or 2 | 84 | 65.707 | 0.875 | 63.993 | 67.422 | ||
| 3 | 23 | 56.300 | 1.542 | 53.277 | 59.323 | ||
| Depth of myometrial invasion | 14.225 | <0.001 | |||||
| <50% | 66 | 66.279 | 0.950 | 64.418 | 68.140 | ||
| ≥50% | 41 | 60.508 | 1.405 | 57.753 | 63.262 | ||
| Lymph node status | 16.602 | <0.001 | |||||
| Negative | 74 | 66.554 | 0.745 | 65.094 | 68.014 | ||
| Positive | 33 | 56.608 | 2.173 | 52.350 | 60.866 | ||
| ER expression | 4.765 | 0.029 | |||||
| Low | 60 | 63.672 | 1.100 | 61.516 | 65.827 | ||
| High | 47 | 65.686 | 1.297 | 63.144 | 68.229 | ||
| PR expression | 7.981 | 0.005 | |||||
| Low | 54 | 62.381 | 1.250 | 59.931 | 64.830 | ||
| High | 53 | 66.591 | 1.093 | 64.449 | 68.733 | ||
| CD147/MMP-2 | 22.230 | <0.001 | |||||
| CD147-/MMP-2- | 42 | 68.051 | 1.128 | 65.840 | 70.263 | ||
| CD147-/MMP-2+ | 17 | 65.692 | 1.452 | 62.847 | 68.538 | ||
| CD147+/MMP-2- | 16 | 61.978 | 1.381 | 59.270 | 64.685 | ||
| CD147+/MMP-2+ | 32 | 58.188 | 2.419 | 53.446 | 62.929 | ||
a
Log-rank test. DSS, disease specific survival; CI, confidence interval; FIGO, International Federation of Gynecology and Obstetrics; ER, estrogen receptor; PR, progesterone receptor.